Dena Tilley
Obstetrics · San Luis Obispo, CANPI 1871705251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,392 and has fallen 97.4% since, to $36 in 2025.
Across 201 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$680
- Biohaven Pharmaceutical Holding Company Ltd.$273
- Takeda Pharmaceuticals U.S.A., Inc.$242
- Novo Nordisk$222
- Therapeuticsmd, Inc.$202
- Lilly USA, LLC$193
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,727100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,727 in reported general payments places this provider in the 80th percentile of 119 obstetrics providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 163 | $10,077 |
| Estradiol (Twice Weekly)Estradiol | 55 | $6,492 |
| ProgesteroneProgesterone, Micronized | 88 | $4,245 |
| DottiEstradiol | 14 | $2,029 |
| Estradiol (Once Weekly)Estradiol | 13 | $1,903 |
| LyllanaEstradiol | 11 | $1,456 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 14 | $1,022 |
| Metronidazole | 11 | $365 |
| Nystatin | 16 | $202 |
| Levothyroxine Sodium | 15 | $180 |
| Fluconazole | 11 | $108 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $75 |
| Sertraline Hcl | 13 | $73 |
Paid to pharmacies, not to this prescriber.
Other obstetrics in San Luis Obispo
- Peter WangGarden Grove$428K
- Douglas Woelkersla Jolla$57K
- Richard FriedmanBurbank$18K
- Jennifer ByerSanta Rosa$17K
- Omar AzizEl Centro$14K
- Frederica LofquistSan Francisco$14K
- Craig SafferSan Diego$14K
- Caitlyn PainterSan Francisco$10K
- Kay DanielsStanford$9K
- Joie RussoEncino$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.